 |
26 Diseases |  |
6 Trials |
|
6 Trials |  |
4342 News |  |
| «12...3132333435363738394041...5051» |
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: #followfriday #medtwitter #cardiology #pocus #cardiotwitter #SoMeDocs #Tweetatricians #cvprev #fishoil #omega3 $amrn #vascepa #endotwitter #jaccclub #FITTweetUp #WIC #womenincardiology #ACCWIC @DocBanks84 @DrMarthaGulati #cardioed @DLBHATTMD (Twitter) - Jan 16, 2020
- | ethyl icosapentate / Generic mfg., Vascepa (icosapent ethyl) / Amarin, HLS Therap
Biomarker, Review, Journal: Understanding why REDUCE-IT was positive - Mechanistic overview of eicosapentaenoic acid. (Pubmed Central) - Jan 15, 2020
At present, it appears that the best mechanistic candidates would be anti-platelet effects and/or anti-inflammatory effects. Whatever the cause, the powerful effects of IPE on CVD risk have renewed interest in the clinical utility of omega-3 fatty acids.
- | ezetimibe / Generic mfg., Vascepa (icosapent ethyl) / Amarin, HLS Therap
Biomarker, Review, Journal: Lipid management beyond the guidelines. (Pubmed Central) - Jan 15, 2020
Icosapent ethyl, a highly concentrated form of modified EPA has been shown to reduce cardiovascular events in high risk patients with moderate hypertriglyceridemia on statin therapy...Epidemiologic pooling studies now clearly show that LDL-C and non-high-density lipoprotein cholesterol levels in young adulthood confer excess risk for ASCVD later in life. Accumulating data support earlier risk factor intervention trials as the next research priority.
- || ezetimibe / Generic mfg., Vascepa (icosapent ethyl) / Amarin, HLS Therap
Biomarker, Clinical, Review, Journal: Implications for REDUCE IT in clinical practice. (Pubmed Central) - Jan 15, 2020
Addition of icosapent ethyl to statins has recently been shown to markedly lower risk of cardiovascular disease (CVD) events in patients with established atherosclerotic CVD (ASCVD) and high risk patients with type II diabetes mellitus. These data are discussed in the context of current guidelines and synthesized in a decision pathway to guide combination lipid-lowering therapy in patients at high ASCVD risk.
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Dr. Allen, you state that you're interested in reversing disease. Please keep an eye on the Evaporate study and do some addl research on Vascepa, Reduce-It and JELIS. That P value means something! (Twitter) - Jan 15, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: I would be interested in the oxylipin profile in Reduce It pts and the impact of Vascepa. (Twitter) - Jan 15, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
In contrast to REDUCE-IT(Vascepa), STRENGTH(Epanova) terminated early due to futility. Impt differ in ingredients. Epanova=EPA/DHA, Vascepa=EPA. Perhaps DHA might impede Epanova in delivering chol/inflam reductions that are impt for CV reduction. @DLBHATTMD #NYPQueens, #EchoFirst (Twitter) - Jan 15, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Retrospective data: Wow. You are truly an idiot. So when you do a meta analysis do you pay no attention to the details of the trials as respects drug composition, dosage, etc? Vascepa/Reduce it stands alone as EPA-only at 4g per day. Who gives a shit about any other omega3 trials with diff makeup? (Twitter) - Jan 14, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Lovaza failed its cardiovascular outcomes trial. Vascepa is the only one that has demonstrated such a large reduction in cardiovascular risk on top of statins. (Twitter) - Jan 14, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Great, Vascepa should be standard of care for many pts. The data is just tooooo goooood! (Twitter) - Jan 14, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: #followfriday #medtwitter #cardiology #pocus #cardiotwitter #SoMeDocs #Tweetatricians #cvprev #fishoil #omega3 $amrn #vascepa #endotwitter #jaccclub #FITTweetUp #WIC #womenincardiology #ACCWIC @DocBanks84 @DrMarthaGulati #cardioed @DLBHATTMD (Twitter) - Jan 14, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: https://t.co/88dQPmGGT0 #followfriday #medtwitter #cardiology #pocus #cardiotwitter #SoMeDocs #Tweetatricians #cvprev #fishoil #omega3 $amrn #vascepa #endotwitter #jaccclub #FITTweetUp #WIC #womenincardiology #ACCWIC @DocBanks84 @DrMarthaGulati #cardioed @DLBHATTMD (Twitter) - Jan 14, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
But also EPA levels with a Epanova in Evolve increased from 25 to 177. In Reduce it Vascepa increased levels from 26 to 140. So EPA dosing is bio equivalent. Needs to be a bad effect of DHA or oxidation effect I’d presume (Twitter) - Jan 14, 2020
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap
Journal, HEOR, Combination therapy: The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. (Pubmed Central) - Jan 14, 2020
These data are discussed in the context of current guidelines and synthesized in a decision pathway to guide combination lipid-lowering therapy in patients at high ASCVD risk. Compared with statin alone, icosapent ethyl in combination with statin therapy is likely to be cost-effective in the prevention of cardiovascular disease assuming a willingness-to-pay threshold of AUD50,000 per QALY gained, especially in the secondary preventive setting.
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Clinical: Are you prescribing Vascepa to your patients with the news of Epanova failure (Twitter) - Jan 13, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Great minds. Was just looking at the same thing but it brought back the mineral oil issue. ApoB went down 2.5% in Vascepa arm but end up 4.5% in placebo arm. Ugh (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Except, Vascepa... (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Since EPA raising is not quite as potent with Epanova as with Vascepa ( although total EPA+DHA increase is modestly higher), the failure of Strength puts more weight on EPA as the CV protective omega-3. I do not believe DHA causes harm. DHA is also important for brain health. (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
ACC/AHA I would hope may update their guidelines now to give icosapent ethyl the strong placement it deserves. @DLBHATTMD @VietHeartPA It would be following several other medical societies. (The others moved very expeditiously). (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Julia brings up a good point about oxidation. Does Epanova have the same anti-oxidation stability formulation like Vascepa? (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Icosapent ethyl is definitely the way 2 go but let's not interpret this as the end of DHA. DHA is vital 4 us! (Twitter) - Jan 13, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Gold Standard: It means pure epa (Vascepa) is the gold standard and all other lipid lowering drugs (not statins) shouldn’t be used!!! Prescribe Vascepa (Twitter) - Jan 13, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical, FDA event: The benefits are already convincing as several global medical societies have swiftly already adopted icosapent ethyl. That does not often happen this speedily. They did not even wait for FDA approval, that’s how convincing the REDUCE-IT trial was @DLBHATTMD @VietHeartPA (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
$AMRN #IcosapentEthyl @DenverChannel features @DLBHATTMD https://t.co/Qo5zsVo85B (Twitter) - Jan 13, 2020
- || CaPre (omega-3 phospholipid) / Acasti Pharma, Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
$MTNB $AMRN $AZN Bad news for Epanova, it’s out, whilst CaPre just had bad news (awaiting more results month end for $ACST) Good news for Vascepa and Matinas ahead. @DLBHATTMD #Cardiology #HeartNews https://t.co/nJQKcSpHOc (Twitter) - Jan 13, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: It seems to me patients in failed trials could/should be moved over to Vascepa. (Twitter) - Jan 13, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: If considering Vascepa, prescribe in patient population studied and explain to patient strengths/limitations of evidence. Though patients for REDUCE-IT trial selected based on high triglycerides, pretty clear than benefit Vascepa *cannot* be explained by TG-lowering (alone) (Twitter) - Jan 13, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: #followfriday #medtwitter #cardiology #pocus #cardiotwitter #SoMeDocs #Tweetatricians #cvprev #fishoil #omega3 $amrn #vascepa #endotwitter #jaccclub #FITTweetUp #WIC #womenincardiology #ACCWIC @DocBanks84 @DrMarthaGulati #cardioed @DLBHATTMD (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Dr. Bhatt always on Twitter to answer the tough questions. Vascepa is the leader in the residual cv space! All supplements and other trig lowering agents should be removed from the markets (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
The much higher risk should@make it easier to see a difference. Vascepa to the control group doesn’t make sense, how much exposure could there be in a year (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
It all makes it hard for me to understand how and when to prescribe Vascepa. And I really don’t know what to do with triglycerides… (Twitter) - Jan 13, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Other possibility is that trial patients were being prescribed vascepa which weakened any possible effect. (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Epanova was theoretically better absorbed than vascepa- so epa dowsing should be similar. Probably a negative effect of dha- which can raise ldl in some (Twitter) - Jan 13, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: Which means that pts received a daIly 2.2 g dose of EPA: 55% of the daily Vascepa dose in Reduce-it. It may make a meaningful difference in blood levels! (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
So it’s: a) 2.2g EPA in Epanova is not enough relative to 4 g in Vascepa? b) .8g DHA in epanova is harmful? c) something else (mineral oil, chance, other...)? (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Do you think potential differences in EPA increases may explain in part the differences in outcomes between REDUCE IT and STRENGTH trials? Vascepa is pure EPA (icosapent ethyl) but Epanova contains both EPA and docosahexaenoic acid (DHA). Discuss this hypothesis (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Yes I think this is a viable hypothesis. It will be interesting to see if Epanova raised EPA levels to the same degree as Vascepa to better understand the causal role of EPA raising in mediating improved outcomes. Benefit may be due to something other than lowering triglycerides. (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
"EPA levels associated with Vascepa may drive the benefit." Is that a viable hypothesis Sek? (Twitter) - Jan 13, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: The futility in the STRENGTH trial is in contrast to the REDUCE IT trial where there was a benefit of high dose omega 3 fatty acids in reducing cardiovascular outcomes indicating that the efficacy of #Vascepa is not a class effect. (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Whoa! It looks like the EPA only eicosapent ethyl is the key to improving CV outcomes! https://t.co/rUlkxFmKaY (Twitter) - Jan 13, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Clinical: Why did REDUCE-IT (purified EPA, Vascepa, 4g a day) succeed in reducing CV outcomes whereas STRENGTH (EPA + DHA, Epanova, 4g a day) failed? This will be a big subject of debate and speculation. @mdavidsonmd developed Epanova at Omthera. What do you think Mike? (Twitter) - Jan 13, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Eating fish for EPA ? EPA comes from algae. Fish collect EPA, (& DHA, parasites, saturated fat) and unless eaten immediately is highly oxidized / putrid within hours. Vascepa from fish means 20 oz unoxidized salmon consumed daily. Unfortunately, that much fish introduces issues (Twitter) - Jan 12, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: @DLBHATTMD question: if Icosapent ethyl was an OTC like Omega 3 in drug stores , do you believe it would be useful for a broader population of patients than trial data shows? Does it have any significant potential harm? (Twitter) - Jan 12, 2020
- |||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical, FDA event: .@DLBhattMD hoped that the results from the randomized clinical trial known as REDUCE-IT would be practice changing. With expanded FDA approval of the prescription drug icosapent ethyl, that hope is becoming a reality. https://t.co/mlY3YkHXex (Twitter) - Jan 11, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Estafando al mundo.... 120 capsules of Vascepa 1g = $268 240 de omega 3 = $18 Pero no es lo mismo verdad ? (Twitter) - Jan 9, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Yep, almost exactly like mine after 9 months on vascepa (Twitter) - Jan 9, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
My 72 year old dad's lipid panel, after being on Vascepa + low dose statin for 2.5 years (compared to LDL in mid 200s and TG in mid 400s) $AMRN @DLBHATTMD @Amarincorp (Twitter) - Jan 9, 2020
- ||| Vascepa (icosapent ethyl) / Amarin, HLS Therap
Clinical: BUYOUT AMRN SOON ! #followfriday #medtwitter #cardiology #pocus #cardiotwitter #SoMeDocs #Tweetatricians #cvprev #fishoil #omega3 $amrn #vascepa #endotwitter #jaccclub #FITTweetUp #WIC #womenincardiology #ACCWIC @DocBanks84 @DrMarthaGulati #cardioed @DLBHATTMD #statins (Twitter) - Jan 9, 2020
- | Vascepa (icosapent ethyl) / Amarin, HLS Therap
There are no reputable brands of pure EPA except Vascepa. (Twitter) - Jan 9, 2020
- || Vascepa (icosapent ethyl) / Amarin, HLS Therap
Check out our review on icosapent ethyl for cardiovascular risk reduction co-written with @skohMD. Thank you to @mahrifai, @rblument1 and @virani_md for the guidance. @BCMHeart https://t.co/yGequCIH6P (Twitter) - Jan 9, 2020